ScholarIQanswers from OpenAlex & ORCID
Kwang‐Hyub Han
ResearcherPublications, citations & collaboration network
Kwang‐Hyub Han is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kwang‐Hyub Han have?
ScholarIQindexed works
Kwang‐Hyub Han has 955 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kwang‐Hyub Han have?
ScholarIQcitation count
Kwang‐Hyub Han has 45,074 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kwang‐Hyub Han?
ScholarIQh-index
Kwang‐Hyub Han has an h-index of 90 in OpenAlex.
What is the i10-index of Kwang‐Hyub Han?
ScholarIQi10-index
Kwang‐Hyub Han has an i10-index of 491 in OpenAlex.
What is the ORCID of Kwang‐Hyub Han?
ScholarIQorcid
The ORCID for Kwang‐Hyub Han is on the source record.
What is the OpenAlex record for Kwang‐Hyub Han?
ScholarIQopenalex
The OpenAlex for Kwang‐Hyub Han is on the source record.
What are the most-cited papers on Kwang‐Hyub Han?
ScholarIQmost cited works
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang‐Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana A. Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei‐Jer Chen, Cosmas Rinaldi Adithya Lesmana, Laurentius A. Lesmana, Rino Alvani Gani, Shuntaro Obi, A. Kadir Dökmeci, Shiv Kumar Sarin
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei‐Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T.P. Poon, Shuichiro Shiina, Ann‐Lii Cheng, Jidong Jia, Shuntaro Obi, Kwang‐Hyub Han, Wasim Jafri, Pierce K. H. Chow, Seng Gee Lim, Yogesh Chawla, Unggul Budihusodo, Rino Alvani Gani, Cosmas Rinaldi Adithya Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson, Shukui Qin, Joong‐Won Park, Ronnie T.P. Poon, Jean‐Luc Raoul, Philip A. Philip, Chih‐Hung Hsu, Tsung‐Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Éveline Boucher, Kwang‐Hyub Han, Seung Woon Paik, Jorge Alberto Robles-Aviña, Masatoshi Kudo, Lünan Yan, Abhasnee Sobhonslidsuk, Д. В. Комов, Thomas Decaens, Won Young Tak, Long‐Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann‐Lii Cheng
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
Hwai‐I Yang, Man‐Fung Yuen, Henry Lik‐Yuen Chan, Kwang‐Hyub Han, Pei‐Jer Chen, Do Young Kim, Sang Hoon Ahn, Chien‐Jen Chen, Vincent Wai‐Sun Wong, Wai‐Kay Seto
Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients
Beom Kyung Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Chae Yoon Chon, Ja Kyung Kim, Yong Han Paik, Kwan Sik Lee, Young Nyun Park, Kwang‐Hyub Han